LA JOLLA, CA – May 12, 2025 – A groundbreaking study from the Salk Institute for Biological Studies has unveiled a critical pathway to combat muscle fatigue and restore energy metabolism, offering a beacon of hope for millions grappling with debilitating conditions ranging from muscular dystrophy to age-related frailty. Published today in the prestigious Proceedings of the National Academy of Sciences, the research identifies a class of proteins known as estrogen-related receptors (ERRs) as indispensable drivers of mitochondrial growth and activity within muscle cells, positioning them as a powerful new therapeutic target.
The findings illuminate a fundamental mechanism by which our bodies generate and utilize energy, a process often disrupted in a myriad of diseases and in the natural course of aging. By demonstrating that ERRs, particularly the alpha subtype (ERRα), can orchestrate the production of more efficient cellular powerhouses—mitochondria—the Salk team has opened an unprecedented avenue for drug development aimed at revitalizing muscle function and systemic metabolic health. This discovery promises to reshape our understanding of metabolic disorders and pave the way for novel treatments that could significantly improve quality of life for those affected.
A New Frontier in Metabolic Repair
At the heart of every cell, tiny, bean-shaped organelles called mitochondria tirelessly convert the food we consume into adenosine triphosphate (ATP), the vital energy currency that powers all biological processes. This cellular-level metabolism is particularly demanding in muscle cells, which require an immense and constant supply of fuel to facilitate movement, strength, and endurance. However, this intricate system is vulnerable to dysfunction. An estimated 1 in 5,000 individuals are born with inherited mitochondrial disorders, while countless others develop metabolic impairments later in life, often associated with the relentless march of aging or the onset of chronic diseases such as cancer, multiple sclerosis (MS), heart disease, and neurodegenerative conditions like dementia.
The consequences of dysfunctional mitochondria are profound and far-reaching, manifesting as chronic fatigue, muscle weakness, reduced physical capacity, and a diminished ability to recover from exertion. Current treatments for these conditions are often limited, focusing primarily on symptom management rather than addressing the root cause of energy depletion. This therapeutic void has spurred scientists to relentlessly search for fundamental mechanisms that could be harnessed to restore mitochondrial health and energy homeostasis.
The Salk Institute’s latest breakthrough reveals that estrogen-related receptors play a surprisingly central role in this vital process. These proteins, which share structural similarities with classic estrogen receptors but operate independently of estrogen hormones, were found to be crucial regulators of muscle cell metabolism, especially during periods of increased energy demand, such as exercise. The research unequivocally demonstrates that ERRs possess the remarkable ability to not only increase the sheer number of mitochondria within muscle cells but also to significantly enhance their energetic output. This dual action positions ERRs as a prime candidate for therapeutic intervention to restore energy supplies in individuals suffering from a spectrum of metabolic disorders, including devastating conditions like muscular dystrophy.
Chronology of Discovery: Unraveling the Nuclear Hormone Receptor Family
The journey to understanding estrogen-related receptors is deeply intertwined with the pioneering work of Dr. Ronald Evans, the senior author of the current study and a distinguished professor and March of Dimes Chair in Molecular and Developmental Biology at the Salk Institute. His illustrious career has been marked by foundational discoveries that have reshaped our understanding of gene regulation and metabolism.
The genesis of this research dates back to the 1980s, a pivotal decade in molecular biology. It was then that Dr. Evans led the landmark discovery of a vast family of proteins he aptly named "nuclear hormone receptors." These extraordinary molecular machines function as sophisticated cellular switches. Activated by various hormones and other signaling molecules, they bind directly to specific sequences of our DNA, acting as master controllers that determine which genes are turned "on" or "off." This intricate dance of gene expression dictates everything from development and growth to metabolism and immunity.
In 1988, building upon this foundational work, Dr. Evans’s laboratory made another significant discovery: the identification of estrogen-related receptors (ERRs) as a distinct branch within this expansive nuclear hormone receptor family. Initially, while their structural resemblance to classic estrogen receptors was noted, their precise physiological functions remained less understood. However, early investigations by Evans’s team were among the first to recognize the budding role of ERRs in the intricate ballet of energy metabolism.
Over the ensuing decades, scientists began to observe that ERRs were often highly expressed in tissues and organs characterized by high metabolic activity and substantial energy demands. The heart, a tireless pump, and the brain, the body’s most energy-hungry organ, were found to be rich in ERRs. This consistent association naturally piqued the curiosity of Evans’s team, leading them to hypothesize a significant, yet unconfirmed, role for ERRs in regulating metabolism within another high-energy organ: skeletal muscle.
Skeletal muscles, the engines of our movement, exhibit an extraordinary capacity for adaptation. When subjected to the demands of physical exercise, they respond by undergoing a process known as mitochondrial biogenesis. During this crucial adaptive response, muscle cells increase both the number and efficiency of their mitochondria, thereby boosting their capacity to generate more fuel. This physiological mechanism underscores the well-established benefits of exercise for overall health and vitality. However, for individuals afflicted with muscular and metabolic disorders, or those weakened by aging or disease, engaging in the necessary levels of physical activity to trigger this beneficial biogenesis is often an insurmountable challenge. This pressing clinical need fueled the Salk scientists’ quest to uncover alternative, pharmacologically targetable pathways to stimulate mitochondrial growth.
Dr. Weiwei Fan, the first author of the study and a staff scientist in Evans’s lab, articulated this motivation clearly: "Mitochondria are our cells’ energy factories, so the more we exercise, the more mitochondria our muscles need. This got us thinking—if we could understand how exercise induces mitochondrial biogenesis, we might be able to target those same mechanisms pharmacologically to trigger this process in people who are too weak to exercise." This strategic shift in focus set the stage for the pivotal experiments that would ultimately reveal the indispensable role of ERRs.
To definitively determine whether estrogen-related receptors played a direct and significant role in muscle cell metabolism, Fan and his colleagues embarked on a meticulously designed series of experiments using genetically modified mouse models. Their approach involved selectively deleting, or "knocking out," the genes encoding three different forms of the estrogen-related receptors—alpha (ERRα), beta (ERRβ), and gamma (ERRγ)—specifically within the muscle tissues of these mice. By systematically removing these receptors, the researchers could then precisely examine the resulting physiological and molecular effects on muscle function and mitochondrial health.
Supporting Data: Unpacking the Mechanism of Muscle Rejuvenation
The detailed investigations conducted by the Salk team yielded compelling evidence, illuminating the intricate interplay between the different ERR subtypes and their collective impact on muscle metabolism. They discovered that while ERRα was the most abundant type of receptor in muscle tissue, its isolated deletion had surprisingly mild impacts under normal, sedentary conditions. This observation initially presented a puzzle. Further probing revealed a fascinating compensatory mechanism: the gamma receptor (ERRγ), despite making up only a small fraction (approximately 4%) of the total estrogen-related receptors, was capable of stepping in and compensating for the loss of ERRα in maintaining baseline mitochondrial function. This intricate redundancy highlights the robustness of biological systems.
However, the picture changed dramatically when both the alpha and gamma types of ERRs were simultaneously deleted. This dual knockout resulted in severe impairments across multiple facets of muscle mitochondrial health, including reduced activity, distorted morphology (shape), and diminished size. These findings underscored the collective importance of ERRs, particularly ERRα and ERRγ, in maintaining the fundamental integrity and function of the cellular powerhouses.
The lingering question of why ERRα was present in such excess, if ERRγ could compensate, prompted the researchers to consider a dynamic scenario: adaptation to stress. They hypothesized that the abundance of ERRα might be critical for muscles to adapt and grow in response to demanding stimuli, such as exercise. To test this hypothesis, the team subjected their genetically modified mice to a regimen of voluntary exercise on mechanical wheels. This exercise protocol reliably triggers mitochondrial biogenesis in healthy muscles, providing an ideal model to assess ERRα’s involvement. The results were striking and definitive: the loss of ERRα alone was sufficient to entirely block exercise-induced mitochondrial biogenesis. This finding solidified ERRα’s status as a critical, non-redundant player in the muscle’s adaptive response to physical activity.
Further deepening their understanding, the Salk team delved into the molecular mechanisms underlying mitochondrial biogenesis. Previous studies had established that exercise-induced mitochondrial growth was largely orchestrated by another protein known as PGC1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). PGC1α has long been celebrated as a "master regulator" of mitochondria throughout the body, capable of enhancing mitochondrial function and increasing their numbers. However, PGC1α presents a significant challenge for therapeutic drug development. Unlike nuclear hormone receptors such as ERRs, PGC1α cannot bind directly to DNA and thus cannot directly activate genes. Instead, it relies on partnering with other proteins to execute its regulatory functions, making it an "indirect" target and considerably more difficult to design drugs that precisely modulate its activity.
It was at this critical juncture that Evans’s lab made another pivotal discovery. When they meticulously examined muscle cells after exercise, they observed that PGC1α was not acting alone; it was forming a crucial partnership with ERRα to drive the process of mitochondrial biogenesis. Crucially, unlike PGC1α, ERRα possesses the inherent ability to bind directly to the DNA sequences of mitochondrial energetic genes and switch them "on." This direct gene-binding capability makes ERRα an exceptionally promising target for the development of therapeutic drugs aimed at enhancing mitochondrial performance within muscle cells. This direct action simplifies the drug design process, as compounds can be developed to directly interact with ERRα, rather than attempting to indirectly influence a complex co-activator like PGC1α.
Official Responses: Voices from the Salk Institute
The implications of this discovery resonated strongly with the lead researchers, who emphasized both the historical context and the future potential of their findings.
Dr. Ronald Evans, reflecting on the long journey of discovery, stated, "Estrogen-related receptors look a lot like classic estrogen receptors, but their function has been much less understood. Our lab discovered estrogen-related receptors in 1988 and was one of the first to recognize their role in energy metabolism. Now we’ve learned that estrogen-related receptors are indispensable drivers of mitochondrial growth and activity in our muscles. This makes them a really promising target to treat muscle weakness and fatigue in many different diseases that involve metabolic dysfunction." His words underscore the culmination of decades of research, from initial identification to the current elucidation of their critical physiological role.
Dr. Weiwei Fan elaborated on the broader systemic benefits that could stem from this targeted approach: "Our findings suggest that activating estrogen-related receptors could not only help fuel people’s muscles, but it could also have other beneficial effects across the whole body. Improving mitochondrial function and energy metabolism could help strengthen many different organ systems, including the brain and heart." This perspective highlights the interconnectedness of cellular metabolism and the potential for a single therapeutic strategy to yield widespread improvements in overall health, extending far beyond the immediate muscular system. The Salk Institute, renowned for its pioneering research in biology and medicine, views this discovery as a significant step towards addressing some of the most challenging health issues of our time.
Implications: A Future of Enhanced Energy and Health
The profound understanding of how estrogen-related receptors function within muscle cells opens a vast landscape of new opportunities for treating a multitude of conditions affected by mitochondrial dysfunction. The immediate and most apparent implication is the potential for developing novel pharmaceutical interventions. Drugs designed to selectively activate or enhance the activity of ERRs, particularly ERRα, could offer a pharmacological "exercise mimetic" – a way to stimulate the beneficial effects of exercise on mitochondrial biogenesis without the physical exertion that is often impossible for patients with severe muscle weakness or fatigue.
This therapeutic strategy holds immense promise for conditions such as muscular dystrophy, a group of genetic diseases characterized by progressive muscle degeneration and weakness. By boosting mitochondrial function, ERR-activating drugs could potentially slow disease progression, improve muscle strength, and enhance endurance. Beyond muscular dystrophy, the applications could extend to other forms of muscle weakness and fatigue, including age-related sarcopenia (the degenerative loss of skeletal muscle mass and strength), chronic fatigue syndrome, and the muscle wasting often seen in cancer patients (cachexia).
Moreover, as Dr. Fan articulated, the benefits are unlikely to be confined to muscle tissue. Given the ubiquitous role of mitochondria in all nucleated cells, and the high expression of ERRs in vital organs like the heart and brain, ERR-targeting drugs could potentially offer systemic improvements. For instance, enhancing cardiac mitochondrial function could be transformative for patients with heart failure, a condition often characterized by impaired myocardial energy metabolism. Similarly, improvements in neuronal mitochondrial health could hold promise for combating cognitive decline in neurodegenerative diseases like Alzheimer’s and Parkinson’s, and for alleviating the devastating neurological symptoms associated with multiple sclerosis.
The path forward for the Salk team involves continued, rigorous investigation. Future research will undoubtedly focus on further dissecting the nuanced functions and precise regulatory mechanisms of both ERRα and ERRγ. Understanding the distinct roles and potential synergistic actions of these receptor subtypes could uncover even more refined and targeted therapeutic strategies. This includes exploring the possibility of developing compounds that selectively modulate specific ERR subtypes for tailored clinical applications.
The development of ERR-activating drugs, while promising, will involve significant research and development efforts. Challenges will include ensuring specificity, minimizing off-target effects, and conducting extensive preclinical and clinical trials to establish safety and efficacy. However, the foundational discovery made by the Salk Institute provides a robust scientific basis for these future endeavors.
Ultimately, the Salk Institute’s discovery represents a significant leap forward in our quest to understand and combat metabolic dysfunction. By pinpointing estrogen-related receptors as key regulators of cellular energy production, this research offers a profound sense of optimism for a future where debilitating muscle fatigue and metabolic disorders can be more effectively treated, leading to enhanced quality of life, greater independence, and improved overall health for millions worldwide. This work, supported by a consortium of prestigious funding bodies including the National Institutes of Health, the Department of the Navy, and various foundations, stands as a testament to the power of fundamental biological research to transform medical possibilities.
About the Author
